
ReShape Lifesciences
Developer of minimally invasive medical devices to treat obesity and metabolic diseases.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | $2.6m | Post IPO Equity |
Total Funding | 000k |









USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 7 % | 2386 % | (25 %) | 20 % | (17 %) | (23 %) | (8 %) |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (6303 %) | (114 %) | (110 %) | (204 %) | (222 %) | (203 %) | (83 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (13369 %) | (492 %) | (191 %) | (455 %) | (411 %) | (131 %) | (89 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 943 % | 21 % | 31 % | 19 % | 23 % | 27 % | 23 % |
Source: Company filings or news article
Related Content
ReShape Lifesciences, Inc. specializes in developing minimally invasive medical devices aimed at treating obesity and metabolic diseases. The company's product portfolio includes the Adjustable Gastric Banding System and the investigational ReShape Vest, which is designed to assist more patients in managing obesity. ReShape Lifesciences operates primarily in the healthcare sector, targeting bariatric surgeons and medical professionals who treat obesity. The company generates revenue through the sale of its medical devices and related services. ReShape Lifesciences is also actively involved in clinical trials, such as the ENDURE II trial in the European Union, to support regulatory approvals and expand its market reach. The business model focuses on innovation in medical technology to provide effective, less invasive treatment options for obesity, thereby improving patient outcomes and expanding its market presence.
Keywords: obesity treatment, metabolic diseases, medical devices, Adjustable Gastric Banding, ReShape Vest, bariatric surgery, healthcare innovation, clinical trials, regulatory approval, patient outcomes.
Tech stack
Investments by ReShape Lifesciences
Edit